Search Results

Analysts at BMO Capital Markets said in a weekend note that a non-invasive blood test could help boost uptake of Alzheimer’s disease therapies.

After years of controversy and allegations of doctored data, Cassava is moving on from Alzheimer’s.

Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s disease (PD), is pleased to announce that it has been selected to present the data from its latest Alzheimer’s study in an extended 45-minute session at the Alzheimer’s Association International Conference® 2024 (AAIC®).

Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially representing a new avenue for treating Alzheimer’s disease.

This year has seen several biopharma companies drop Alzheimer’s and Parkinson’s disease programs, but experts say plenty are still chasing these multi-billion-dollar markets.

The deal helps revitalize the TREM2 target after the high-profile failure of AbbVie and Alector’s candidate last year.

The darlings of the weight loss and diabetes spaces, GLP-1 receptor agonists have shown promise against Alzheimer’s in recent studies—with Phase III results expected next year from Novo Nordisk.